文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

携带DDX41变异的髓系恶性肿瘤患者的特征与临床结局

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
PubMed 文献 · Am J Hematol · 2023-09-04

研究分析3795例髓系肿瘤患者,鉴定出151例(4%)携带DDX41变异,其中急性髓系白血病(AML)96例、骨髓增生异常综合征(MDS)52例、慢性粒单核细胞白血病3例。初治AML和MDS的总缓解率分别为87%和84%,中位总生存期分别为49个月和71个月;AML患者中接受含维奈克拉低强度方案者2年总生存率优于未含维奈克拉者(91% vs 60%,p=.02)。

要点

  • 3795例髓系肿瘤中151例(4%)携带DDX41变异,主要为AML(96例)和MDS(52例)。
  • 初治AML和MDS总缓解率分别为87%和84%,中位总生存期分别为49和71个月。
  • AML患者含维奈克拉低强度方案较不含者2年总生存率更高(91% vs 60%,p=.02)。

核心结论

  • 携带DDX41变异的髓系恶性肿瘤患者对治疗反应良好,接受含维奈克拉低强度方案的AML患者生存改善、复发累积发生率更低。

研究设计与样本

  • 研究分析了3795例髓系肿瘤患者,鉴定出151例(4%)携带DDX41变异,诊断为AML(n=96)、MDS(n=52)和慢性粒单核细胞白血病(n=3)。

主要发现

  • 最常见的DDX41变异为体细胞变异p.R525H,其次为胚系变异p.M1I和p.D140fs。
  • 多数肿瘤核型正常(59%),最常见的共突变为TP53(16%)和ASXL1(15%),30%的患者除DDX41变异外无其他伴随突变。
  • 初治AML和MDS的总缓解率分别为87%和84%,中位总生存期分别为49和71个月。
  • AML患者中接受含维奈克拉低强度方案者较未含维奈克拉者2年总生存率更高(91% vs 60%,p=.02),复发累积发生率更低(10% vs 56%,p=.03)。
  • 33%的患者接受造血干细胞移植,AML和MDS的2年总生存率分别为80%和85%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DDX41 is the most frequently mutated gene in myeloid neoplasms associated with germline predisposition including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We analyzed 3795 patients with myeloid neoplasms and identified 151 (4%) with DDX41 variants and a diagnosis of AML (n = 96), MDS (n = 52), and chronic myelomonocytic leukemia (n = 3). The most frequent DDX41 variants were the somatic variant p.R525H, followed by the germline variants p.M1I and p.D140fs. Most neoplasms had a normal karyotype (59%) and the most frequent co-mutations were TP53 (16%) and ASXL1 (15%). 30% of patients had no concomitant mutations besides DDX41 mutation. Patients with myeloid malignancies and DDX41 variants responded well to therapy, with an overall response rate for patients with treatment naïve AML and MDS of 87% and 84%, respectively. The median overall survival (mOS) of patients with treatment-naïve AML or MDS was 49 and 71 months, respectively. Patients with AML treated with low-intensity regimens including venetoclax had an improved survival (2-year OS 91% vs. 60%, p = .02) and lower cumulative incidence of relapse compared to those treated without venetoclax (10% vs. 56%, p = .03). In the 33% of patients receiving hematopoietic stem cell transplantation, the 2-year OS was 80% and 85% for AML and MDS, respectively.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bataller A, Loghavi S, Gerstein Y, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023. PMID: 37665752. doi:10.1002/ajh.27070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。